Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...
The prospects of the latter two companies looked better following the European pharmaceutical's new clinical trial readout.
Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...
Deutsche Bank analyst James Shin has maintained their bullish stance on LLY stock, giving a Buy rating on September 16. James Shin has given ...
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...
Eli Lilly said on Friday the U.S. Food and Drug Administration approved its eczema drug for use in adults and children above ...
On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and children 12 and ...
Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights ...